Primary hyperparathyroidism in MEN1 patients: A cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype

Annals of Surgery

Volumn 255, Issue 6, 2012, Pages 1171-1178

  Pieterman, Carolina R C ^a   Van Hulsteijn, Leonie T ^a,c   Den Heijer, Martin ^b,d   Van Der Luijt, Rob B ^a   Bonenkamp, J J ^b   Hermus, Ad R M M ^b   Rinkes, Inne H M Borel ^a   Vriens, Menno R ^a   Valk, Gerlof D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; VITAMIN D;

ADOLESCENT; ADULT; AUTOTRANSPLANTATION; CALCIUM BLOOD LEVEL; CANCER SURGERY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; ENDOCRINE SURGERY; ENDOCRINOLOGY; EXON; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENOTYPE; HUMAN; INFORMATION PROCESSING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE ENDOCRINE NEOPLASIA; NETHERLANDS; NONSENSE MUTATION; PARATHYROID GLAND; POSTOPERATIVE COMPLICATION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SURGICAL TECHNIQUE; THYMECTOMY; UNIVERSITY HOSPITAL; VITAMIN BLOOD LEVEL;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPOPARATHYROIDISM; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROIDECTOMY; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861340925     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824c5145     Document Type: Review

References (42)

1. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404-407.
2. Goudet P,Murat A, Binquet C, et al. Risk factors and causes of death inMEN1 disease.AGTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34:249-255.
3. Lourenco DM, Jr, Toledo RA, Coutinho FL, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics. 2007;62:465-476.
4. Pieterman CR, Schreinemakers JM, Koppeschaar HP, et al. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf). 2009;70:575-581.
5. Schaaf L, Pickel J, Zinner K, et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes. 2007;115:509-517. (Pubitemid 350056763)
6. Vierimaa O, Ebeling TM, Kytola S, et al. Multiple endocrine neoplasia type 1 in Northern Finland: clinical features and genotype phenotype correlation. Eur J Endocrinol. 2007;157:285-294. (Pubitemid 47603532)
7. Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg. 2009;33:1208-1218.
8. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery. 1998;124:1106-1113; discussion 1113-1114.
9. Berglund G, Liden A, Hansson MG, et al. Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). Fam Cancer. 2003;2:27-33. (Pubitemid 36534536)
10. Dean PG, van Heerden JA, Farley DR, et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg. 2000;24:1437-1441.
11. Wilson SD, Krzywda EA, Zhu YR, et al. The influence of surgery in MEN-1 syndrome: observations over 150 years. Surgery. 2008;144:695-701; discussion 701-702.
12. Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24:1404-1410.
13. Dotzenrath C, Cupisti K, Goretzki PE, et al. Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg. 2001;167:173-178. (Pubitemid 32231953)
14. Hellman P, Skogseid B, Juhlin C, et al. Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1. World J Surg. 1992;16:718-722; discussion 722-723.
15. O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114:1031-1037; discussion 1037-1039.
16. Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg. 1998;133:126-129. (Pubitemid 28092908)
17. Prinz RA, Gamvros OI, Sellu D, et al. Subtotal parathyroidectomy for primary chief cell hyperplasia of the multiple endocrine neoplasia type I syndrome. Ann Surg. 1981;193:26-29. (Pubitemid 11130868)
18. Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003;134:858-864; discussion 864-865.
19. Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124:993-999. (Pubitemid 28555184)
20. Hubbard JG, Sebag F, Maweja S, et al. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg. 2006;141:235-239.
21. Kraimps JL, Duh QY, Demeure M, et al. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112:1080-1086; discussion 1086-1088.
22. Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005;140:374-382. (Pubitemid 40489957)
23. Lee CH, Tseng LM, Chen JY, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 1: individualized management with low recurrence rates. Ann Surg Oncol. 2006;13:103-109.
24. Malmaeus J, Benson L, Johansson H, et al. Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: choice of surgical procedure. World J Surg. 1986;10:668-672. (Pubitemid 16096425)
25. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247:501-510.
26. Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007;246:1075-1082. (Pubitemid 350179202)
27. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257:27-37. (Pubitemid 40129124)
28. Hubbard JG, Sebag F, Maweja S, et al. Primary hyperparathyroidism in MEN 1-how radical should surgery be? Langenbecks Arch Surg. 2002;386:553-557. (Pubitemid 34285634)
29. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patientswith multiple endocrine neoplasia type 1.AmJHumGenet. 1998;62:232-244. (Pubitemid 28110764)
30. Waldmann J, Lopez CL, Langer P, et al. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg. 97: 1528-1534.
31. Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002;137:641-647. (Pubitemid 34603007)
32. Turner JJ, Leotlela PD, Pannett AA, et al. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2002;87:2688-2693. (Pubitemid 34655331)
33. Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20:35-47. (Pubitemid 34747715)
34. Langer P, Wild A, Schilling T, et al. Multiple endocrine neoplasia type 1. Surgical therapy of primary hyperparathyroidism [in German]. Chirurg. 2004;75:900-906. (Pubitemid 39360454)
35. Bartsch DK, Langer P, Wild A, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128:958-966.
36. Arnalsteen LC, Alesina PF, Quiereux JL, et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2002;132:1119-1124; discussion 1124-1125.
37. Goudet P, Cougard P, Verges B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Neoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25:886-890. (Pubitemid 32666389)
38. Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008;144(6):878-883; discussion 883-884.
39. SalmeronMD, Gonzalez JM, Sancho Insenser J, et al. Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J Surg. 34:1325-1331.
40. Dreijerink KM, Mulder KW,Winkler GS, et al. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 2006;66:4929-4935.
41. Dreijerink KM, Varier RA, van Beekum O, et al. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferatoractivated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol. 2009;29:5060-5069.
42. Dreijerink KM, Varier RA, van Nuland R, et al. Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol Cell Endocrinol. 2009;313:1-8.